Medeon Biodesign, Inc. (TPEX: 6499)
Taiwan
· Delayed Price · Currency is TWD 43.30
-0.50 (-1.14%)
Nov 21, 2024, 12:14 PM CST
Medeon Biodesign Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -810.63 | -1,205 | -433.76 | 2,078 | -192.74 | -261.99 | Upgrade
|
| Depreciation & Amortization | 93.59 | 93.62 | 61.77 | 58.02 | 82.13 | 77.21 | Upgrade
|
| Other Amortization | 2.06 | 2.05 | 2.03 | 0.99 | 2.14 | 2.05 | Upgrade
|
| Loss (Gain) From Sale of Assets | 5.76 | 13.01 | - | - | - | 0.04 | Upgrade
|
| Loss (Gain) From Sale of Investments | 1.61 | 399.15 | -0.68 | -2,507 | - | - | Upgrade
|
| Loss (Gain) on Equity Investments | - | -13.54 | -47.69 | -19.66 | - | - | Upgrade
|
| Stock-Based Compensation | 14.48 | 15.69 | 3.11 | 5.95 | 0.5 | 7.19 | Upgrade
|
| Provision & Write-off of Bad Debts | 2.88 | 0.58 | - | -0.36 | -0.33 | 0.6 | Upgrade
|
| Other Operating Activities | -149.67 | -89.68 | -76.96 | -2,607 | -185.29 | 4.37 | Upgrade
|
| Change in Accounts Receivable | -5.16 | -9.99 | 5.3 | 39.65 | -92.07 | -26.71 | Upgrade
|
| Change in Inventory | -8.87 | -0.71 | -4.4 | -10.04 | -11.9 | -22.45 | Upgrade
|
| Change in Accounts Payable | 11.02 | 1.42 | 2.87 | 4.42 | 2.55 | 12.84 | Upgrade
|
| Change in Unearned Revenue | 3.8 | 2.25 | 0.21 | -8.18 | -6.52 | -61.24 | Upgrade
|
| Change in Other Net Operating Assets | 22.97 | 35.7 | 26.86 | 36.56 | 21.78 | 26.11 | Upgrade
|
| Operating Cash Flow | -816.16 | -755.08 | -461.34 | -293.38 | -151.27 | -241.99 | Upgrade
|
| Capital Expenditures | -57.94 | -55.29 | -140.57 | -8.32 | -20.16 | -48.9 | Upgrade
|
| Cash Acquisitions | - | - | -165.89 | 4.21 | - | - | Upgrade
|
| Divestitures | - | - | - | 450.92 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.86 | -0.52 | -0.15 | -0.7 | -0.99 | -2.43 | Upgrade
|
| Investment in Securities | -19.18 | 1,643 | 552.91 | -535.92 | 270.12 | -268.36 | Upgrade
|
| Other Investing Activities | 1.24 | 8.64 | 17.13 | -0.83 | -3.34 | -0.98 | Upgrade
|
| Investing Cash Flow | -76.74 | 1,596 | 263.44 | -90.64 | 245.63 | -320.66 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 12.94 | - | Upgrade
|
| Long-Term Debt Repaid | - | -47.89 | -29.17 | -17.4 | -21.36 | -20.29 | Upgrade
|
| Total Debt Repaid | -46.88 | -47.89 | -29.17 | -17.4 | -21.36 | -20.29 | Upgrade
|
| Net Debt Issued (Repaid) | -46.88 | -47.89 | -29.17 | -17.4 | -8.42 | -20.29 | Upgrade
|
| Issuance of Common Stock | 3.85 | 0.23 | - | 10.1 | 0.08 | 662.83 | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | -20.48 | - | Upgrade
|
| Common Dividends Paid | -43.82 | -43.82 | -73.03 | - | - | - | Upgrade
|
| Other Financing Activities | 0.26 | 0.91 | 1.05 | 3.4 | 594.65 | 68.71 | Upgrade
|
| Financing Cash Flow | -86.6 | -90.57 | -101.16 | -3.9 | 565.84 | 711.26 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.02 | 4.09 | 47.64 | -4.89 | -4.12 | -4.66 | Upgrade
|
| Net Cash Flow | -979.53 | 754.07 | -251.42 | -392.81 | 656.07 | 143.95 | Upgrade
|
| Free Cash Flow | -874.11 | -810.36 | -601.91 | -301.69 | -171.44 | -290.89 | Upgrade
|
| Free Cash Flow Margin | -412.58% | -412.90% | -201.77% | -437.51% | -139.32% | -64.11% | Upgrade
|
| Free Cash Flow Per Share | -9.49 | -8.80 | -6.54 | -3.28 | -1.87 | -3.18 | Upgrade
|
| Cash Interest Paid | 6.15 | 6.64 | 4.6 | 1.55 | 3.28 | 2.74 | Upgrade
|
| Cash Income Tax Paid | 87.06 | 59.94 | 69.21 | 4.35 | 39.24 | 4.41 | Upgrade
|
| Levered Free Cash Flow | -579.08 | -455.87 | -416.46 | -89.12 | -213.07 | -48.57 | Upgrade
|
| Unlevered Free Cash Flow | -575.24 | -451.72 | -413.2 | -88.48 | -212.21 | -46.86 | Upgrade
|
| Change in Net Working Capital | 74.42 | -17.46 | 34.49 | -165.31 | 62.24 | -78.84 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.